logo
Plus   Neg
Share
Email

Hillenbrand To Buy Milacron In $2 Bln Deal

Hillenbrand Inc. (HI) said that it agreed to buy Milacron Holdings Corp. (MCRN) in a cash and stock transaction valued at about $2 billion, including net debt of about $686 million.

As per the terms of the agreement, Milacron stockholders will receive $11.80 in cash and a fixed exchange ratio of 0.1612 shares of Hillenbrand common stock for each share of Milacron common stock they own.

In Friday pre-market trade, MCRN is trading at $16.77 up $3.24 or 23.95 percent.

Based on Hillenbrand's closing stock price on July 11, 2019, the implied cash and stock consideration to be received by Milacron stockholders is $18.07 per share, representing a premium of about 34% to Milacron's closing stock price on July 11, 2019.

Upon closing of the transaction, Hillenbrand shareholders will own about 84% of the combined company, and Milacron stockholders will own about 16%.

The transaction, which is expected to close in the first calendar quarter of 2020, is expected to deliver double-digit adjusted earnings per share accretion in the first year following close.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
Follow RTT